Stopping Arthritis Drugs Before COVID Shots Raises Flare Risk Without Boosting Immunity
A randomized trial of 840 arthritis patients finds pausing DMARDs before COVID vaccination doubles flare risk with no antibody benefit.
Summary
A randomized trial called COVER enrolled 840 patients with inflammatory arthritis — mostly rheumatoid arthritis — and tested whether temporarily stopping biologic or targeted immunosuppressant drugs (DMARDs) before COVID vaccination improved immune responses. Participants were assigned to either a two-week drug hold or continued their usual treatment. Results showed antibody responses were virtually identical between groups, while those who stopped their medications were more than twice as likely to experience an arthritis flare. Published in JAMA Internal Medicine, the findings settle a lingering pandemic-era question: pausing these drugs offers no immunological advantage and meaningfully harms disease control. The takeaway for autoimmune patients and their doctors is clear — don't interrupt targeted DMARD therapy around COVID vaccine scheduling.
Detailed Summary
During the early COVID-19 vaccine rollout, a practical question arose for the millions of people living with inflammatory arthritis: should immunosuppressant drugs be paused temporarily to allow vaccines to work better? Biologic and targeted disease-modifying antirheumatic drugs (DMARDs) dampen immune activity, raising legitimate concerns about whether they might blunt vaccine-generated antibody responses. Some clinicians informally recommended short drug holidays without firm evidence to support the practice.
The COVER trial was launched in late 2021 specifically to answer this question rigorously. Researchers at the University of Alabama at Birmingham and collaborators enrolled 840 patients — 602 with rheumatoid arthritis, 198 with psoriatic arthritis, and 40 with spondyloarthritis — and randomized them equally to either a two-week DMARD hold around vaccination or continued therapy as normal.
The primary outcome was change in immunoglobulin G antibodies against the SARS-CoV-2 spike protein six weeks post-vaccination. The result: the fold-rise in antibody levels was nearly identical between groups (ratio 0.96, 95% CI 0.36–2.56), meaning the drug hold produced no measurable immunological gain. On the harm side, however, the drug-hold group was more than twice as likely to experience an arthritis flare (OR 2.27, 95% CI 1.41–3.65), confirmed both by patient self-report and by the validated OMERACT Rheumatoid Arthritis Flare Questionnaire.
For the autoimmune disease community, these findings carry direct implications for managing long-term health. Arthritis flares are not trivial events — they erode physical function, increase pain, and can accelerate joint damage over time. Preserving disease control is itself a healthspan priority for this population.
The authors conclude that routine temporary interruption of targeted DMARDs for COVID-19 vaccine optimization is not supported by evidence. Clinicians and patients managing autoimmune conditions can now rely on trial-level data rather than precautionary intuition when scheduling future vaccinations.
Key Findings
- A 2-week DMARD pause before COVID vaccination produced no improvement in spike-protein antibody responses in 840 arthritis patients.
- Pausing targeted DMARDs more than doubled the odds of an arthritis flare compared with continuing therapy (OR 2.27).
- Results held across rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis patient groups.
- The COVER trial provides the first rigorous randomized evidence to settle this pandemic-era clinical question.
- Authors conclude routine DMARD interruption for vaccine optimization should not be standard practice.
Methodology
This is a news report summarizing a prospective, randomized controlled trial (COVER) published in JAMA Internal Medicine, a high-credibility peer-reviewed journal. The trial enrolled 840 participants across multiple arthritis subtypes with a clearly defined primary outcome and quantitative flare assessment tools. Data analysis began in 2024, covering a well-defined intervention window.
Study Limitations
The article is a 3-minute news summary and the full trial data are not reproduced, so granular subgroup analyses and secondary endpoints require verification in the primary JAMA Internal Medicine publication. The trial was unblinded by necessity, which may have influenced patient-reported flare outcomes. Findings apply specifically to targeted DMARDs and may not generalize to conventional synthetic DMARDs like methotrexate.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: